BOCH
SGMT icon

Blue Owl Capital Holdings’s Sagimet Biosciences SGMT Stock Holding History

Blue Owl Capital Holdings’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.74M Sell
333,877
-910,000
-73% -$5.07M 0.47% 33
2025
Q4 		$7.36M Sell
1,243,877
-84,474
-6% -$607K 2.27% 12
2025
Q3 		$9.11M Hold
1,328,351
– – 2.83% 11
2025
Q2 		$10.1M Hold
1,328,351
– – 3.27% 9
2025
Q1 		$4.33M Buy
1,328,351
+4,474
+0.3% +$18.8K 1.4% 19
2024
Q4 		$5.96M Sell
1,323,877
-350,000
-21% -$1.77M 1.37% 18
2024
Q3 		$4.64M Hold
1,673,877
– – 0.89% 26
2024
Q2 		$5.72M Hold
1,673,877
– – 1.59% 18
2024
Q1 		$9.07M Buy
1,673,877
+1,318,500
+371% +$9.47M 1.81% 16
2023
Q4 		$1.93M Buy
+355,377
New +$1.68M 0.46% 30

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Blue Owl Capital Holdings's SGMT Position: Q1 2026 in Review

Blue Owl Capital Holdings reduced its Sagimet Biosciences (SGMT) stake by 73% in Q1 2026, selling an estimated $5.07M and leaving 333,877 shares worth $1.74M. The position accounts for 0.47% of the portfolio, ranked #33.

Blue Owl Capital Holdings first reported a position in SGMT in Q4 2023 and has held it in 10 quarters since. The position peaked at $10.1M in Q2 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Blue Owl Capital Holdings held 333,877 shares of Sagimet Biosciences worth $1.74M as of Q1 2026.
  • Blue Owl Capital Holdings sold 910,000 Sagimet Biosciences shares in Q1 2026, an estimated $5.07M.
  • Sagimet Biosciences made up 0.47% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #33 holding.
  • Blue Owl Capital Holdings first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 10 quarters since.
  • Blue Owl Capital Holdings's Sagimet Biosciences position peaked at $10.1M in Q2 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.